What do systematic reviews say?

Telephone‐based disease monitoring vs face‐to‐face monitoring

It is very uncertain whether telephone‐based disease monitoring changes flare‐ups/relapse (dichotomous; adults) compared with face‐to‐face monitoring (very low certainty).

• Remote care through telehealth for people with inflammatory bowel disease 2023 · Cochrane Headline outcomes only
  RR 1.17 [0.47, 2.89]
  1 study · 42 participants
  Very low

Web‐based disease monitoring vs self‐screening

• Remote care through telehealth for people with inflammatory bowel disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 102 participants
  Very low

Web‐based disease monitoring vs usual care

Web‐based disease monitoring showed no clear difference in flare‐ups/relapse (dichotomous; adults) compared with usual care (moderate certainty).

• Remote care through telehealth for people with inflammatory bowel disease 2023 · Cochrane Headline outcomes only
  RR 1.09 [0.93, 1.27]
  5 studies · 868 participants
  Moderate